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Background: To understand the carcinogenesis caused by accumulated genetic and epigenetic alterations and
seek novel biomarkers for various cancers, studying differentially expressed genes between cancerous and normal
tissues is crucial. In the study, two cDNA libraries of lung cancer were constructed and screened for identification of
differentially expressed genes.
Methods: Two cDNA libraries of differentially expressed genes were constructed using lung adenocarcinoma tissue
and adjacent nonmalignant lung tissue by suppression subtractive hybridization. The data of the cDNA libraries
were then analyzed and compared using bioinformatics analysis. Levels of mRNA and protein were measured by
quantitative real-time polymerase chain reaction (q-RT-PCR) and western blot respectively, as well as expression and
localization of proteins were determined by immunostaining. Gene functions were investigated using proliferation
and migration assays after gene silencing and gene over-expression.
Results: Two libraries of differentially expressed genes were obtained. The forward-subtracted library (FSL) and the
reverse-subtracted library (RSL) contained 177 and 59 genes, respectively. Bioinformatic analysis demonstrated that
these genes were involved in a wide range of cellular functions. The vast majority of these genes were newly
identified to be abnormally expressed in lung cancer. In the first stage of the screening for 16 genes, we compared
lung cancer tissues with their adjacent non-malignant tissues at the mRNA level, and found six genes (ERGIC3,
DDR1, HSP90B1, SDC1, RPSA, and LPCAT1) from the FSL were significantly up-regulated while two genes (GPX3 and
TIMP3) from the RSL were significantly down-regulated (P < 0.05). The ERGIC3 protein was also over-expressed in
lung cancer tissues and cultured cells, and expression of ERGIC3 was correlated with the differentiated degree and
histological type of lung cancer. The up-regulation of ERGIC3 could promote cellular migration and proliferation
in vitro.
Conclusions: The two libraries of differentially expressed genes may provide the basis for new insights or clues for
finding novel lung cancer-related genes; several genes were newly found in lung cancer with ERGIC3 seeming a
novel lung cancer-related gene. ERGIC3 may play an active role in the development and progression of lung
cancer.
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Lung cancer is the leading cause of cancer-related death
and the global five-year survival rate is only 10% to 15%.
Lung cancer is also more variable in its biological behav-
ior and can be divided into two histological groups:
small-cell lung cancer (SCLC) and non-small cell lung
cancer (NSCLC). NSCLC which accounts for approxi-
mately 80% of all lung cancers, includes adenocarcinoma
(AC), squamous cell carcinoma (SCC) and large-cell car-
cinoma. The incidence of adenocarcinoma appears to be
increasing globally.
Cancer is the result of the accumulation of genetic and
epigenetic alterations, which in turn means there are dif-
ferent profiles of gene expression in various lung cancers
[1]. Studying differentially expressed genes between cancer
and normal tissues is crucial to understanding carcinogen-
esis and identifying novel biomarkers for cancer [2,3].
Several technologies are available to obtain profiles of the
differentially expressed genes: representational difference
analysis, serial analysis of gene expression, oligonucleotide
microarrays, or suppression subtractive hybridization
(SSH) [4], among others. SSH is a polymerase chain reac-
tion (PCR)-based cDNA subtraction technique that allows
selective amplification of target cDNA while simultan-
eously suppressing non-target cDNA amplification. The
cDNA library generated by hybridization and subtraction
techniques reduces abundantly expressed housekeeping
genes or genes commonly expressed in both control and
treated individuals, thereby normalizing the cDNA expres-
sion profiles during library construction [4]. As a result,
this technique significantly enhances the chances of differ-
entially expressed genes [5]. SSH has been successfully ap-
plied to a wide variety of malignant diseases including
lung cancer for the generation of cDNA libraries [6-10].
In previous studies, samples were obtained from either
culture cells or tissues from different individuals. The in-
herent problem in this sampling was that the SSH li-
brary generated using cultured cells may provide some
incorrect information, because genes could have varied
or mutated. Similarly, the SSH library constructed using
tissues of different individual leads to the problem that
the differentially expressed genes in various individuals
could not be neutralized during hybridization, and these
genes could be incorrectly deemed as being cancer-
related. To correct these shortfalls, we used lung AC tis-
sue and its adjacent nonmalignant lung tissue to establish
two cDNA libraries by SSH, to obtain more accurate in-
formation of differentially expressed genes in lung ACs.
After genome BLAST, 177 up-regulated and 59 down-
regulated genes in lung ACs were obtained from the
forward-subtracted library (FSL) and the reverse-subtracted
library (RSL), respectively. Further bioinformatic analysis
demonstrated that these genes were involved in a wide
range of cellular functions. The vast majority of these geneswere newly identified to be abnormally expressed in
lung cancer. Subsequently, we selected 16 differentially
expressed genes to investigate their mRNA levels on
lung cancer tissue samples as the first stage of screen-
ing. According to real-time RT-PCR analysis, DDR1,
HSP90B1, SDC1, RPSA, ERGIC3, and LPCAT1 were up-
regulated significantly in NSCLCs, while GPX3, TIMP3
were down-regulated significantly. ERGIC3 is located
in endoplasmic reticulum and Golgi apparatus of NRK
cells [11], however, the function of ERGIC3 is unclear in
lung cancer. Therefore, expression of ERGIC3 in
NSCLCs was further confirmed at the protein level by
western blot and immunohistochemistry analysis and
we studied the pathophysiological functions of ERGIC3.Methods
Patients and tissue samples
The primary tumors and adjacent nonmalignant lung
tissues were obtained at the time of surgery and quickly
frozen in liquid nitrogen. No patients were treated be-
fore undergoing surgical resection. The adjacent nonma-
lignant lung tissues which were away from the cancer
tissues at least 5 cm, did not contain cancer cells but
usually appeared inflammatory response and fibrosis.
Pathological diagnosis was based on light microscopy
according to the World Health Organization classifica-
tion [12]. Tumors were staged according to TNM cri-
teria published by the International Union Against Cancer
in 1997 [13]. Tumor regions selected for RNA and protein
isolation contained a tumor cellularity greater than 60%.
The use of all of the human tissue samples and the experi-
mental procedures for this study were reviewed and
approved by the Tumor Hospital of Yunnan Province and
Kunming Institute of Zoology. All researches were carried
out according to the Helsinki Declaration.Cell culture
Six lung cancer cell lines and an immortalized human
bronchial epithelial cell line (BEAS-2B) were used.
A549 (AC), 801-D (large cell carcinoma), NCI-H446
(SCLC), and BEAS-2B were obtained from Cell Bank of
Kunming Institute of Zoology, Chinese Academy of
Sciences (CAS, Kunming, China); SPCA-1 (AC) was
purchased from the Cell Bank of Type Culture Collec-
tion, CAS (Shanghai, China); EPLC-32M1 (SCC) and
GLC-82 (AC) were obtained from German Cancer Re-
search Center (Heidelberg, Germany) and Chinese Na-
tional Cancer Institute, Chinese Academy of Medical
Sciences (Beijing, China), respectively. The BEAS-2B
cell line was fed with DMEM, while the other cell lines
were cultured with RPMI 1640 containing 10% fetal bo-
vine serum (FBS) and maintained in a humidified incu-
bator with 5% CO2 at 37°C.
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To construct the SSH library, we used a tumor tissue
and its adjacent nonmalignant lung tissue derived from
one patient with well-differentiated lung adenocarcin-
oma. The tumor tissue contained a tumor cellularity
greater than 80%. The adjacent nonmalignant lung tissue
was away from the cancer tissues at least 10 cm and
appeared completely normal histological structure. To-
tal RNA was isolated using TRIzol (Invitrogen Corp.,
Carlsbad, CA, USA). Poly(A)+ RNA was isolated using the
PolyATtractW mRNA isolation systems (Promega Corp.,
Madison, WI, USA). The cDNA synthesis and subtraction
were performed using the PCR-select™ cDNA subtraction
kit (Clontech, Palo Alto, CA, USA). Using the cDNA
of lung adenocarcinoma tissue as tester and its adja-
cent nonmalignant lung tissue as driver, we generated
the FSL which represented up-regulated transcripts. Using
the cDNA of lung adenocarcinoma tissue as driver and
its adjacent nonmalignant lung tissue as tester, the RSL
which represented down-regulated transcripts, was con-
structed. The subtracted cDNA fragments obtained in
each experiment were cloned into the pGEM-T Easy vec-
tor (Promega Corp.) and used to transform E.coli strain
DH5α cells. All the transformants were isolated from
white colonies on X-gal/isopropyl-beta-D-thio-galatopyra-
noside agar plates.
Quantitative real-time polymerase chain reaction (q-RT-
PCR)
Total RNA was isolated from lung cancer tissues and ad-
jacent nonmalignant tissues using TRIzol (Invitrogen
Corp.). RNA was used as a template to synthesize the
first strand cDNA with M-MLV reverse transcriptase
(Promega Corp.). The q-RT-PCR reactions were per-
formed on an ABI stepone™ real-time RT-PCR system
using the SYBR Green dye method. The q-RT-PCR
reactions were performed in 25 μl volumes that included
0.5 μl of SYBR green, 8 ng of cDNA template and 1.0 μl
each of the forward and reverse primers (10 μM) (see
Additional file 1). The PCR was done under the condi-
tions at 94°C for 30 seconds, then 40 cycles of amplifica-
tion at 94°C for 30 seconds, 60°C for 30 seconds. Each
gene was normalized to the internal β-actin levels. Each
sample was run in triplicate to ensure quantitative ac-
curacy, and the threshold cycle numbers (Ct) were aver-
aged. The results were reported as tumor tissues: normal
tissues (T:N) ratios and calculated using the 2−ΔΔCt
method [14].
Western blot
Total protein was extracted from cultured cells and tis-
sues, separated by electrophoresis, and then transferred
into PVDF membrane according to the routine protocol.
The blotted membrane was incubated with the rabbitanti-ERGIC3 polyclonal antibody (Sigma-Aldrich, St.
Louis, MO, USA) followed by horseradish peroxidase-
conjugated anti-rabbit secondary antibody (AbMART,
Shanghai, China), and then proteins were detected with
chemiluminescence reagents (Thermo Fisher Scientific
Inc., Waltham, MA, USA). The membrane was reprobed
with an antibody against β-actin (Abcam, Cambridge,
UK) as a control for equivalent protein loading.
Immunohistochemical staining
Immunohistochemical staining was done on 4-μm-thick
paraffin sections cut from the formalin fixed tissues.
Heat-induced epitope retrieval was performed in Tris-
EDTA Buffer (10 mM Tris Base, 1 mM EDTA Solution,
0.05% Tween 20, pH 9.0). The sections were then incu-
bated in 3% H2O2 for 10 minutes to eliminate endogen-
ous peroxidase activity. The primary rabbit anti-ERGIC3
polyclonal antibody (Abcam) and horseradish peroxidase-
conjugated anti-rabbit secondary antibody were used. Color
development was accomplished with 3,3'-Diaminobenzidin.
The nuclei were then counterstained with hematoxylin.
Only manifest cytoplasmic staining was defined as a posi-
tive reaction. Negative controls were incubated with normal
rabbit serum instead of the polyclonal antibody.
Immunofluorescence staining and confocal microscopy
Immunofluorescence analysis was done on the cultured
cells. Briefly, the cells grown on coverslips were fixed in
−20°C acetone for 10 minutes and then incubated with
the rabbit anti-ERGIC3 polyclonal antibody (Abcam),
and anti-MUC1 mouse monoclonal antibody (mAb) A76-
A/C7 (Glycotope, Berlin, Germany), anti-ST mAb [15],
anti-calreticulin mAb (Abcam), and anti-58K Golgi protein
mAb (Abcam) at 4°C overnight. Following the washes, the
cells were incubated with FITC-coupled anti-rabbit anti-
body (BD sciences, Franklin Lakes, NJ, USA) or with Cy3-
coupled anti-mouse antibody (Millipore, Billerica, MA,
USA) for 1 hour. Subsequently, the nuclei were finally
counterstained with diamidinophenylindole. The slides
were analyzed under confocal laser scanning microscopy.
Construction of the expression vector and the cell
transfection
To generate the plasmid expressing ERGIC3, we cloned
the open reading frame of ERGIC3 and used the follow-
ing specific primers (upper case, restriction enzyme
sequences): forward, 5'-GGTGGTGAATTCatgaggcgctg
gggaagct-3'; reverse,5'-GGTGGTGGATCCaccgaggagggt
gactacgttgtctt-3'. After running PCR, the product was
cut by EcoR I and BamH I. The purified DNA was
ligated into the pLXSN expression vector (Clontech
Corp.). The empty vector served as a control. The vec-
tors were transfected into BEAS-2B cell by lipofecta-
mine LTX and PLUS (Invitrogen Corp.) according to
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validated by q-RT-PCR and western blot.
Gene silencing by RNA interference
For gene silencing of ERGIC3, pGPU6/GFP/Neo-
ERGIC3-shRNA and its control vector, pGPU6/GFP/
Neo-NC-shRNA, were used (Jima Corp., Shanghai,
China). Briefly, the oligonucleotide GGAGGACTATC
CAGGCATTGT was designed to interfere specifically
with ERGIC3 gene expression. As a negative control,
we used the oligonucleotide GTTCTCCGAACGTGT
CACGT, which has no significant match in a BLASTn
search (human NCBI nr database). The vectors were
transfected into GLC-82 cells by lipofectamine LTX
and PLUS. The gene silencing of ERGIC3 was validated
by q-RT-PCR and western blot.
Cell proliferation assay
Cell proliferation analysis was based on the capacity of
mitochondrial enzymes to transform MTT to MTT for-
mazan. More succinctly, after being transfected for 48
hours, GLC-82 and BEAS-2B were collected and trans-
ferred into 96-well plates (4*103 cells/well), then all cells
were treated with MTT (5 mg/ml) every 24 hours. 10 μl
of MTT was added to each well and cells were incubated
at 37°C for 2 hours. Then, the culture medium with dye
was removed and dimethylsulfoxide was added at 100 μl
per well for formazan solubilization. The absorbance of
converted dye was measured at a wavelength of 490 nm
using a 96-well microplate reader (model 680, Bio-Rad
Laboratories).
Cell migration assay
The transfected GLC-82 and BEAS-2B cells were used
for the cell migration assay. The transwell migration
assay was conducted in 24 well plates with membrane
inserts (8 mm pore size; Millipore). The cells were then
seeded in the upper chamber of transwells (105 cells/
well) without FBS. The lower chambers were loaded
with 500 μl of medium with 10% FBS. After incubation
for 24 hours, filters were washed and the cells on the
upper surface were gently removed with a cotton swab.
The cells were fixed with 95% ethanol, and were stained
by Giemsa I (Jiancheng Corp. Nanjing, China) and Giemsa
II. The cells were then counted under microscope. The
experiments were repeated three times.
Statistical analysis
Measurement data (levels of mRNA and protein, the data
of cellular migration and proliferation) and enumeration
data (the data of immunohistochemical staining) were re-
spectively analyzed using the paired t-test and the Fisher’s
exact test (two-tailed). All of the values were evaluatedusing IBM SPSS 19 (SPSS inc., Chicago, Illinois). Differ-
ences were considered significant if P < 0.05.
Results
Generation of SSH cDNA libraries
Using SSH, two cDNA libraries were constructed with
the primary lung AC tissue derived from a single patient.
From the FSL library, 485 subtractive cDNA clones were
obtained, representing genes up-regulated in tumor tis-
sues. Meanwhile, from the RSL library, 172 subtractive
cDNA clones were obtained, representing genes down-
regulated in tumor tissues. Using the BLAST algorithm
at NCBI RefSeq, GenBank, and dbEST, we detected 177
genes and 44 unknown expressed sequence tags (ESTs)
in the FSL as well as 59 genes and 10 unknown ESTs in
the RSL. Further bioinformatic analysis demonstrated
the major functions of these genes were related molecu-
lar transport, cellular signaling and interaction, cellular
polarization, cell cycle, cell apoptosis, cellular growth
and proliferation, cellular movement, DNA replication,
recombination and repair (see Additional file 2 and 3).
Eight earlier constructed SSH libraries of lung cancer
(five FSLs and three RSLs) were available for us to ob-
tain gene expression profiles [6-10]. From the previous
five FSLs, 152 genes from our FSL were not reported.
Similarly, 54 genes in our RSL were not present in the
previous three RSLs. In the six aggregated FSLs from
our study and earlier publications, 42 genes appeared
twice, while four genes (EEF1A1, FTH1, GSTP1, STAT1)
appeared three times (see Additional file 4). Additionally,
in the four RSLs from our study and the three previous,
only six genes (ANXA8, CAV1, CEBPD, GPX3, TPM3,
NACA) appeared twice. Among those six, CAV1, CEBPD,
GPX3, TPM3 and NACA were present in our RSL (see
Additional file 5).
mRNA expression of a part of differentially expressed
genes in lung cancer tissues
As a first stage analysis, we selected 16 genes among the
differentially expressed genes from our FSL and RSL li-
braries for further study based on two criteria: 1) The 10
genes were previously reported in lung cancer while six
were not reported; 2) These genes belong to importantly
functional genes. We examined mRNA expression of 16
genes selected from the SSH libraries using q-RT-PCR.
Among the 16 genes, two were selected from the RSL,
one from both the RSL and FSL, and 13 from the FSL.
The percentage of the altered expression in the tumor
tissues compared to their adjacent nonmalignant lung
tissues is shown in Table 1. The mRNA levels of the 16
genes in the lung cancer tissues were compared with
those in the adjacent nonmalignant lung tissues using
the paired t-test. The two genes selected from the RSL
were significantly down-regulated in the tumor tissues
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sues (GPX3, P = 0.000 and TIMP3, P = 0.000), and six
genes selected from the FSL were significantly up-regulated
in the lung cancer tissues (DDR1, P = 0.009; HSP90B1, P =
0.000; SDC1, P = 0.007; RPSA, P = 0.013; ERGIC3, P =
0.000; and LPCAT1 P = 0.036). However, seven genes
selected from FSL (FOXA2, C4BPA, SCGB3A1, DDX58,
CCNDBP, TMSB4X, and CXCL17), and one gene selected
from both FSL as well as RSL (CD9), were up-regulated in
the lung cancer tissues, but not significantly (P > 0.05). The
tendency of the seven genes expressions was consistent
with that of the FSL which represented genes up-regulated
in cancer tissues. We noted that CD9, present in both the
FSL and RSL, was increased in 41.2% of lung cancer cases.Table 1 Altered expression of the 16 genes in lung cancer tis
tissues using quantitative RT-PCR (q-RT-PCR)
Gene Library Percentage Main Functions
GPX3 RSL ↓ 85% (29/34)# Detoxification of hydrogen pero
prostate cancer growth and me
TIMP3 RSL ↓ 85% (29/34) Degradation of the extracellular
checking inflammation. Cell inv
death.
CD9 RSL & FSL ↑ 41% (14/34) Functions in many cellular proc
differentiation, adhesion, and si
Suppression of cancer cell moti
DDR1 FSL ↑ 74% (25/34) Communication of cells with th
Regulation of cell growth, differ
metabolism.
HSP90B1 FSL ↑ 82% (28/34) Molecular chaperones with role
folding other proteins. Associat
pathogenic states.
FOXA2 FSL ↑ 29% (10/34) Transcriptional activators for live
Maintenance of glucose and lip
Suppressor of tumor metastasis
SDC1 FSL ↑ 82% (28/34) Regulation of cell proliferation,
matrix interactions.
C4BPA FSL ↑ 35% (12/34) Activation of the complement c
SCGB3A1 FSL ↑ 56% (19/34) Inhibition of cell growth and in
RPSA FSL ↑ 65% (22/34) Implication of biological proces
adhesion, differentiation, migrat
outgrowth and metastasis.
ERGIC3 FSL ↑ 76% (47/62) Regulation of cell growth and e
stress-induced cell death. Prote
early secretory pathway.
DDX58 FSL ↑ 47% (29/62) Regulation of immune response
CCNDBP1 FSL ↑ 47% (29/62) Inhibition of cell cycle. Suppres
TMSB4X FSL ↑ 37% (23/62) Regulation of actin polymerizat
proliferation, migration, and diff
CXCL17 FSL ↑ 45% (28/62) Anti-inflammatory factor. Promo
LPCAT1 FSL ↑ 47% (29/62) Catalyzing the conversion of LP
phosphatidylcholine (PC) in the
PC biosynthesis. Promotion of c
↓: Down-regulation of the genes in lung cancer tissues compared with their adjacen
tissues compared with their adjacent nonmalignant lung tissues; #: Number of casePerhaps the presence of CD9 in the RSL was a false signal.
Over-expression of two genes (ERGIC3 and LPCAT1) had
not been previously linked to lung cancer. We opted to
focus on ERGIC3 in this study.Expression of ERGIC3 mRNA in cultured cells
Similar to the results we found in lung cancer tissues,
in the lung cancer cell lines, the mRNA levels of
ERGIC3 showed up to 44.9- (in SPCA-1), 61.4- (in
EPLC-32M1), 60.8- (in GLC-82), 22.1- (in NCI-H446),
16.0- (in A549), 32.1- (in 801D) fold increase, com-
pared to the immortalized normal bronchial epithelial
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cancer tissues by western blot
Expression of the ERGIC3 protein was analyzed using
western blot. Expression of ERGIC3 was increased in
67% (10/15) of the tumor cases (Figure 1A). Similarly,
expression of ERGIC3 protein was increased in all three
lung cancer cell lines by comparison with the BEAS-2B
(Figure 1B).
Subcellular localization of ERGIC3 protein in cultured cells
In cultured cells, the subcellular localization of ERGIC3
was examined by immunofluorescence double-staining
using markers of the Golgi apparatus and endoplasmic
reticulum (ER). ERGIC3 was mainly located at the Golgi
apparatus and ER in the lung cancer cell lines. Interest-
ingly, ERGIC3 was distributed at the side of nucleus in
EPLC-32M1, 801D, and NCI-H446 cells, but uniformly
present around nucleus in SPCA-1, GLC-82 and A549
cells (Figure 2).
We also found that ERGIC3 was co-localized with the
epithelia mucin MUC1 and β-Galactoside α2,6 Sialyl-
transferase (ST), which were principally located at the
ER and Golgi apparatus in the cultured cells (Figure 2).
Expression and localization of the ERGIC3 protein in lung
cancer tissues by immunohistochemical staining
Expression and localization of the ERGIC3 protein was
further investigated by immunohistochemistry in 35
cases of NSCLC. ERGIC3 was diffusely distributed in the
cytoplasm of tumor cells but not expressed in normal
bronchial epithelial cells and alveolar cells (Figure 3).
The antibody of ERGIC3 used in the study was the poly-
clonal anti-ERGIC3 serum, this may be the reason that
the non-specific staining appeared in nucleus.Figure 1 Semi-quantitative analysis of the ERGIC3 protein by western
and their adjacent nonmalignant tissues (N). (B) The averages of protein le
BEAS-2B. The Y-axis shows the ratio of the ERGIC3 grey value divided by th
test (two tailed). *: P < 0.05.ERGIC3 was positive in 89% of (31/35) NSCLCs, and
strongly stained in 63% (22/35). Interestingly, the positive
rate of AC (100%, 22/22) was higher than that of SCC
(69%, 9/13). In poorly differentiated NSCLCs, 36% (4/11)
cases were not stained. We noticed that all of negative
specimens were poorly differentiated tumor cells, and the
staining was decreased to the largest extent and even dis-
appeared in poorly differentiated NSCLCs, compared with
well and moderately NSCLCs (P <0.05). No correlations
were observed between expression of ERGIC3 and the
gender as well as smoking histories of the patients and
TNM stage (Table 2).
Effects of ERGIC3 expression on the proliferation of the
epithelial cells
In order to study whether altered expression of ERGIC3
affects the cell proliferation, GLC-82 (with the high level
of endogenous ERGIC3) and BEAS-2B cells (with the low
level of endogenous ERGIC3) were used in the study. In
GLC-82 cells, compared with the cells transfected with
the control vector, the expression of ERGIC3 was reduced
by RNA interference. While the expression of ERGIC3 in
BEAS-2B cells was increased after the transfection with
the expression vector. The altered expression of ERGIC3
was indicated by q-RT-PCR (Figure 4A,B) and western
blotting (Figure 4C,D). We found the reduced expression
of ERGIC3 in GLC-82 significantly reduced the rate of cell
proliferation (Figure 4E), and the over-expression of
ERGIC3 in BEAS-2B cells significantly increased the rate
of cell proliferation (Figure 4F).
Effects of ERGIC3 expression on the cellular migration
We also analyzed the impact of ERGIC3 on cellular mi-
gration. The expression of ERGIC3 in GLC-82 andblot. (A) The averages of protein levels in the 15 tumor tissues (T)
vels in three separate experiments on SPCA-1, GLC-82, EPLC-32M1 and
e beta-actin grey value. The significance was evaluated by a paired t-
Figure 2 Subcellular colocalization of ERGIC3 in cultured cells.
ERGIC3 [green] with calreticulin (CRT), Golgi protein (GP), MUC1, and
β-galactoside α2,6 sialyltransferase (ST) [red] in lung cancer cell lines,
SPCA-1 and EPLC-32M1. Nuclei were stained by
diamidinophenylindole [blue]. Scale bar: 10 μm.
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lencing and over-expression, as described earlier. The
treated cells were used for the transwell migration assay
based on Boyden Chamber. We found that the lower-
expression of ERGIC3 could inhibit the cellular migra-
tion in GLC-82 (Figure 5A), and the over-expression of
ERGIC3 could promote the cellular migration in BEAS-
2B (Figure 5B).
Discussion
Differentially expressed genes are the fundamental driver
of both the diversity and complexity of tumor pheno-
types. Generating subtracted cDNA libraries is the first
step in identifying genes differentially expressed in can-
cer cells. This construction is made easier by the simple
and highly effective suppression subtractive hybridization
(SSH) technique. SSH has been successfully applied to a
wide variety of malignant diseases for the generation of
cDNA libraries [6-10].
In this study, we constructed two libraries of differen-
tially expressed genes using the lung AC tissue and its
adjacent nonmalignant lung tissue from a single patient.
We compared and analyzed the results from all the lung
cancer SSH libraries, including our own. Surprisingly,
most of the differentially expressed genes were unequal
in these libraries. This could be explained that diverse
cancer tissues and cell lines lead to different gene ex-
pression profiles. The genetic abnormality of cancer
appears a great diversity. Accordingly, using various sam-
ples to generate new cDNA libraries in order to find novel
differentially expressed genes in lung cancer can play a
significant role in advancing research into lung cancer. In
this regard, our SSH libraries add useful data that can fur-
ther be used in the discovery of lung cancer-associated
genes. Indeed, the vast majority of the differentially
expressed genes of our libraries were not known to be ab-
normally expressed in lung cancer.
Bioinformatics analysis was subsequently performed to
interpret the differentially expressed genes of our FSL
and RSL libraries. The functions of these genes were
involved in several aspects: molecular transport; cellular
signaling and interaction; cellular polarization; cell cycle;
DNA replication, recombination, and repair; cell apop-
tosis; cellular growth and proliferation; cellular move-
ment. Here we would like to emphasize several interesting
facts observed during this study. 1) 12.4% (22/177) of our
FSL was ribosomal protein genes but these proteins only
made up 1.7% (1/59) of the genes found in our RSL. The
large amount of ribosomal proteins up-regulated in the
lung AC tissues from this data seems to indicate that
thriving cancer cells need plenty of ribosomal proteins. 2)
Cancer is a multi-genetic disease. Individual tumors accu-
mulate an average of 90 mutant genes [16]. In our study,
the results based on the two libraries of differentially
Figure 3 Immunohistochemical staining of ERGIC3 in the lung cancer tissues and normal lung tissues. ERGIC3 was strongly stained in the
cytoplasm of tumor cells on lung adenocarcinomas (A) and squamous cell carcinomas (B), but it was negative in the ciliated epithelium (C) and
normal respiratory epithelium (D). Original magnification, ×200 (A.B), ×100 (C.D).
Table 2 Immunohistochemical staining of ERGIC3 in lung
cancer tissues
Characteristic ERGIC3− ERGIC3+ P-value
Gender 0.279
Male 3/17 (18%)# 14/17 (82%)





No 1/17 (6%) 16/17 (94%)
Yes 3/18 (17%) 15/18 (83%)
Histological type 0.014*
AC 0 22/22 (100%)
SCC 4/13 (31%) 9/13 (69%)
TNM stage 0.419
I + II 3/20 (15%) 17/20 (85%)
III + IV 1/15 (7%) 14/15 (93%)
Differentiation 0.006*
Poor 4/11 (36%) 7/11 (64%)
Well or Moderate 0 24/24 (100%)
Statistical significance was determined by the Fisher’s exact test of chi-square
test (two-tailed); #: Number of cases applicable/total number of cases
examined (with percent in parenthesis); *: Statistically significant, P < 0.05.
Abbreviations: SCC: squamous cell carcinoma; AC: adenocarcinoma; y: year.
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more than 200 genes simultaneously exhibited abnor-
mal expression and the number of the up-regulated
genes was more than that of the down-regulated genes,
indicating that even in a tumor the genetic abnormality
is greatly extensive and complex. Although the case
which was used to construct the libraries is very limited,
the study would also have provided clues to the trend of
gene expression alterations.
A large fraction of the differentially expressed genes
found in cancer were likely to be “passenger” genes that
are not to be integral to neoplasia. However, screening
of “non-passenger” genes (functionally important altera-
tions) among the differentially expressed genes and study-
ing their functions are helpful for the elucidation of
tumorigenesis mechanisms and the discovery of new diag-
nostic and therapeutic targets. As a first stage analysis, 16
genes were selected among the differentially expressed
genes from our FSL and RSL libraries for further study.
Through q-RT-PCR analysis, we found six genes (DDR1,
HSP90B1, SDC1, RPSA, ERGIC3, and LPCAT1) signifi-
cantly up-regulated and two genes (GPX3 and TIMP3) sig-
nificantly down-regulated in the lung cancer tissues.
Among the eight genes significantly up- or down-regulated
in the lung cancers in this study, the six genes have been
noted in previous studies for the connection between their
expression and lung cancer: up-regulated DDR1 [17],
HSP90B1 [18], SDC1 [19], and RPSA [20], as well as down-
regulated GPX3 [21] and TIMP3 [22]. Importantly, this
means that for the first time, over-expression of ERGIC3
and LPCAT1 have been linked to lung cancer. LPCAT1
may contribute to total choline metabolite accumulation
via phosphatidylcholine remodeling, thereby altering thecolorectal cancer lipid profile, a characteristic of malig-
nancy [23], but this was investigated in a separate work as
the current study focuses on ERGIC3.
ERGIC3 (previously labeled Erv46, ERp43) is an inte-
gral membrane protein that cycles between the ER and
Figure 4 Expression of ERGIC3 and cellular proliferation. The levels of ERGIC3 mRNA were evaluated by q-RT-PCR in GLC-82 cells after ERGIC3
gene silencing (A) and in BEAS-2B cells after ERGIC3 over-expression (B). And the levels of ERGIC3 protein were evaluated by western blot in
GLC-82 cells after ERGIC3 gene silencing (C) and in BEAS-2B cells after ERGIC3 over-expression (D). Reduced expression of ERGIC3 could slow the
proliferation rates of GLC-82 cells (E), but increased expression of ERGIC3 could enhance the proliferation rates of BEAS-2B cells (F). Differences in
cell proliferation rates were analyzed by a paired t-test (two tailed). NC: negative control; ERGIC3i: ERGIC3 gene silencing; pLXSN: treated with the
pLXSN vector; pLXSN-ERGIC3: treated with the pLXSN-ERGIC3 vector. *: P < 0.05; **: P < 0.01.
Figure 5 Expression of ERGIC3 and cellular migration. Reduced expression of ERGIC3 could demote the migration of GLC-82 cells (A), but
increased expression of ERGIC3 could promote the migration of BEAS-2B cells (B). Differences in numbers of migration cells were analyzed by a
paired t-test (two tailed). NC: negative control; ERGIC3i: ERGIC3 gene silencing; pLXSN: treated with the pLXSN vector; pLXSN-ERGIC3: treated with
the pLXSN-ERGIC3 vector. *: P < 0.05.
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lumen, and its short N- and C-terminal tail sequences
expose to the cytosol and the two transmembrane seg-
ments each, which would be available for protein-
protein interactions in the ER lumen or membrane [26].
Through the systematic and serial screening, we found
that the ERGIC3 mRNA and protein were highly over-
expressed in lung cancer cells. In the cultured cells,
ERGIC3 was mainly located at the Golgi apparatus and
ER, in agreement with previous descriptions [11]. We
observed that the distribution of ERGIC3 was associated
with the cellular shape. In the round cells, ERGIC3 was
located around the nucleus, but it was at the side of the
nucleus in the fusiform cells. This phenomenon indi-
cates that the localization of ERGIC3 is identical to the
distribution of the Golgi apparatus and ER. ERGIC3 may
be a well marker of the Golgi apparatus and ER in can-
cerous cells.
We also found that ERGIC3 was closely co-localized
with MUC1 and ST. MUC1 is a high molecular weight
transmembrane glycoprotein. The protein backbone of
MUC1 is synthesized at the ER and glycosylated at the
Golgi apparatus. ST is a key enzyme that sialylates lacto-
saminyl termini of complex type oligosaccharides in an
α2,6 linkage. ST is located predominantly in the trans-
Golgi network, and could be secreted by some cells [27].
ERGIC3 is involved in the protein transport between the
ER and the Golgi apparatus. We guess that ERGIC3
could participate in the transport of MUC1 and ST from
the ER to the Golgi apparatus. Further studies will hope-
fully address this issue.
In our study, ERGIC3 was found positive in 89% speci-
mens of lung cancer by immunohistochemical staining.
In contrast, ERGIC3 was not expressed in normal bron-
chial epithelial cells and alveolar cells. These results
from our pilot study suggested that ERGIC3 may be a
potential biomarker for lung cancer. However, more
studies must be performed to permit final conclusions.
Our laboratory has already begun the relevant research.
We further investigated pathophysiological functions
of the altered expression of ERGIC3 in lung cancer cells.
In our study, over-expressed ERGIC3 promoted the cel-
lular proliferation. A recent study demonstrated that
ERGIC3 played important roles in cell growth and ER
stress-induced apoptosis [28]. Additionally, we also found
that up-regulation of ERGIC3 facilitated cellular migra-
tion. The cellular proliferation and migration are essential
events during carcinogenesis and cancerous invasion.
ERGIC3 may play an active role in the development and
progression of lung cancer. At present, the full mechan-
isms by which ERGIC3 promotes cellular proliferation
and migration are not understood. Previous studies
demonstrated that Erv41p-Erv46p complex interacts with
glucosidase II and modulates glucosidase I activity, as wellas cells lacking a cycling Erv41p-Erv46p complex display a
mild glycoprotein processing defect [26], and the mutation
of ERGIC3 could reduce the transport between the ER
and the Golgi apparatus [29]. It is then tempting to specu-
late that abnormally expressed ERGIC3 could affect the
cellular proliferation and migration through the disruption
of glucosidase activity and protein intracellular transport.
Conclusions
We used SSH to generate two cDNA libraries (FSL and
RSL) of differentially expressed genes. The 177 up-
regulated and 59 down-regulated genes in lung cancer
were obtained. The vast majority of these genes were
linked to lung cancer for the first time. In the first stage
of the screening for 16 genes, two novel lung cancer-
related genes (ERGIC3 and LPCAT1) were found.
ERGIC3 was strongly expressed in lung cancers, and
that ERGIC3 could promote the cellular proliferation
and migration. These findings suggest that ERGIC3 may
play an active role in the development and progression
of lung cancer. Consequently, our two libraries of differ-
entially expressed genes may provide the basis for new
insights or clues for finding novel lung cancer-related
genes. Hopefully, several serious studies will be made
on the data we collected in these two libraries.
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